Cyclerion Therapeutics, Inc. (CYCN)

↓ Download CSV

CIK 0001755237 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated MA
  • Fiscal year ends Dec 31

In fiscal 2025, Cyclerion Therapeutics, Inc. reported revenue of $2.07M, up 3.7% from the prior year. The company ran a net loss, with a net margin of -170.1%.

Key ratios (FY2025)

-239.8%
Operating margin
-170.1%
Net margin
-38.8%
Return on equity
+3.7%
Revenue growth (YoY)
Metric (FY)202520242023202220212020201920182017
Revenue$2.07M$2.00M$0$297.0K$3.94M$2.30M
Operating Income-$4.97M-$3.63M-$12.95M-$18.54M-$55.20M-$81.27M-$125.04M-$115.25M
Net Income-$3.53M-$3.06M-$5.26M-$44.08M-$51.65M-$77.80M-$123.01M-$115.25M
EPS (Diluted)$-1.11$-1.21$-2.25$-20.28$-1.32
Total Assets$9.98M$9.57M$13.37M$18.08M$59.33M$115.38M$186.48M$7.40M
Shareholders' Equity$9.09M$8.85M$11.29M$10.45M$48.25M$59.49M$97.73M-$10.45M-$8.57M
Cash & Equivalents$3.24M$3.23M$7.57M$13.38M$53.96M$54.40M$94.89M
Operating Cash Flow-$3.31M-$4.33M-$21.25M-$40.61M-$36.52M-$72.49M-$102.22M-$97.50M
Capital Expenditures$0$7.0K$1.52M$6.89M$3.44M
Shares Outstanding3.82M2.55M2.47M2.18M43.41M34.05M27.60M0